Holman: Follow-on Biologics Bill Threatens Innovation By Weakening Patent Rights

Patently BIOtech

Chris Holman, Professor at the University of Missouri-Kansas City School of Law and author of Holman’s Biotech IP Blog, recently posted a great summary of the patent provisions in the follow-on biologics bill currently under consideration in Congress.

You can read Holman’s post here.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags:

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>